PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aurinia Pharmaceuticals Inc. (AUPH)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCA05156V1022
CUSIP05156V102
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$718.75M
EPS-$0.54
Revenue (TTM)$175.51M
Gross Profit (TTM)$83.38M
EBITDA (TTM)-$74.14M
Year Range$4.94 - $12.43
Target Price$11.29
Short %8.40%
Short Ratio3.79

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with AUPH

Aurinia Pharmaceuticals Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aurinia Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%OctoberNovemberDecember2024FebruaryMarch
-96.78%
347.96%
AUPH (Aurinia Pharmaceuticals Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Aurinia Pharmaceuticals Inc. had a return of -44.38% year-to-date (YTD) and -54.50% in the last 12 months. Over the past 10 years, Aurinia Pharmaceuticals Inc. had an annualized return of 5.24%, while the S&P 500 had an annualized return of 10.96%, indicating that Aurinia Pharmaceuticals Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-44.38%10.04%
1 month-16.67%3.53%
6 months-37.34%22.79%
1 year-54.50%32.16%
5 years (annualized)-5.13%13.15%
10 years (annualized)5.24%10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-16.13%-24.14%
2023-21.68%-14.33%-5.53%17.71%4.05%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
AUPH
Aurinia Pharmaceuticals Inc.
-0.92
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Aurinia Pharmaceuticals Inc. Sharpe ratio is -0.92. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.92
2.76
AUPH (Aurinia Pharmaceuticals Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aurinia Pharmaceuticals Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-97.33%
0
AUPH (Aurinia Pharmaceuticals Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aurinia Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aurinia Pharmaceuticals Inc. was 99.47%, occurring on Sep 10, 2012. The portfolio has not yet recovered.

The current Aurinia Pharmaceuticals Inc. drawdown is 97.33%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.47%Apr 11, 2002756Sep 10, 2012
-36.58%Aug 31, 200146Feb 8, 200214Apr 9, 200260
-10.61%Jul 25, 20012Aug 2, 20015Aug 22, 20017
-2.49%Aug 27, 20011Aug 27, 20011Aug 29, 20012

Volatility

Volatility Chart

The current Aurinia Pharmaceuticals Inc. volatility is 7.36%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%OctoberNovemberDecember2024FebruaryMarch
7.36%
2.82%
AUPH (Aurinia Pharmaceuticals Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aurinia Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items